Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda's Patents Cited in Largest Number of Notices of Reasons for Patent Refusal
May 23, 2011
- Teva to Buy 57% Stake in Taiyo for ¥37 Bil.
May 23, 2011
- Domestic Sales of New Drugs Contribute to Growth: Otsuka HD
May 23, 2011
- Daiichi Sankyo: Growth in Sales, Double-digit Rise in Profits
May 23, 2011
- Korosho Asks Kyokai-kenpo to Further Promote Use of Generics
May 23, 2011
- Astellas: Sales, Profits Down on Lower Overseas Sales of Prograf, Harnal
May 23, 2011
- Generics Market Share Up to 23.1% in FY2010 3rd Qtr: JGA
May 23, 2011
- Eisai: Sales Down for First Time in 12 Fiscal Years
May 23, 2011
- PMDA Committee to Offer Proposals to Shorten Pre-review Period
May 23, 2011
- Achieving CO2 Emissions Target to Remain Priority in FY2011: JPMA
May 23, 2011
- PMDA Introduces 12-Team System to Evaluate ADR Information
May 23, 2011
- Astellas Announces Changes in Top Leadership
May 16, 2011
- Assessing Contamination Risk Important in Wake of Nuclear Accident: Mr Igari of JPMA
May 16, 2011
- Takeda Submits 2 sNDAs for Velcade in the US
May 16, 2011
- Expectations High for BI Japan's Prazaxa, 1st Novel Oral Anticoagulant in Half a Century
May 16, 2011
- Japan Is Best Positioned to Help China Strengthen Its New Drug Development Capability: Mr Hasegawa
May 16, 2011
- Chugai Files for Add'l Indication for Herceptin Based in Info in Public Domain
May 16, 2011
- MSs from Wholesalers Provide Valuable Services in Emergency, MRs Feel Small
May 16, 2011
- Japanese Economy Threatened by “Serious Illness” New Keizai Doyukai Chairman Mr Hasegawa
May 16, 2011
- Actemra Approved for SJIA as Additional Indication in US
May 16, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…